/
Corporate Information We were incorporated under the laws of the State of Delaware in 2003. Our company, formerly known as GlycoMimetics, Inc., is a biotechnology company that is the result of a reverse recapitalization transaction with a private company named Crescent Biopharma, Inc. ( Pre-Merger Crescent ).
The business is unprofitable at the operating level (-1407.52% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -$72M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$11M
Net Income (TTM)
-$162M
▼ -306.4% YoY
Op. Margin
-1407.52%
ROIC
-79.39%
▲ +27.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$71M
▼ -132.9% YoY
Op. Cash Flow (TTM)
-$70M
▼ -130.0% YoY
Net Debt
-$188M
Net Cash Position
Cash & Equiv.
$189M
5Y CAGR: +257.8%
Continue Research